ad image

Nivolumab

1 / 1
X4 Pharmaceuticals
Clinical Data

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals

PR-M05-18-NI-068May 17, 2018
1 / 1